Patients with stiff person syndrome are one step closer to having access to a new treatment. Kyverna Therapeutics’ new drug, KYV-101, has been designated by the U.S. Food and Drug Administration (FDA) a Regenerative Medicine Advanced Therapy (RMAT), the company announced on Monday. A drug is eligible for RMAT designation if it is “intended to…